Cargando…

New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center

BACKGROUND: Fear of cancer progression/recurrence (FOP/FCR) is considered one of the most prevalent sources of distress in cancer survivors and associated with lower quality of life and functional impairment. Detailed measures of FOP/FCR are needed because little is known about the knowledge of FOP/...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefner, Jochen, Berberich, Sara, Lanvers, Elena, Sanning, Maria, Steimer, Ann-Kathrin, Kunzmann, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694194/
https://www.ncbi.nlm.nih.gov/pubmed/29180853
http://dx.doi.org/10.2147/PPA.S142784
_version_ 1783280090897973248
author Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
author_facet Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
author_sort Hefner, Jochen
collection PubMed
description BACKGROUND: Fear of cancer progression/recurrence (FOP/FCR) is considered one of the most prevalent sources of distress in cancer survivors and associated with lower quality of life and functional impairment. Detailed measures of FOP/FCR are needed because little is known about the knowledge of FOP/FCR, its associations with the patient–doctor relationship, and the rate of adequate therapy. Colorectal cancer (CRC) is one of the most prevalent cancer entities, and oral capecitabine is widely prescribed as treatment. Therefore, we initiated a pilot study to expand the literature on FOP/FCR in CRC outpatients receiving capecitabine and to generate hypotheses for future investigations. METHODS: This study included 58 patients treated at a comprehensive cancer center. FOP/FCR was assessed with the Fear of Progression Questionnaire (FOP-Q-SF). Satisfaction with the relationships with doctors was assessed with the Patient–Doctor Relationship Questionnaire-9 (PRDQ-9). Levels of side effects were rated by the patients on a visual analog scale. Clinical data were extracted from the charts. RESULTS: A total of 19 out of 58 patients (36%) suffered from FOP/FCR according to our assessment. Levels of FOP/FCR seemed to be mostly moderate to high. Only four out of the 19 distressed patients (21%) were treated accordingly. Typical side effects of oncological treatment were associated with higher FOP/FCR. Satisfaction with doctor–patient relationships was not associated with FOP/FCR. Regarding single items of FOP/FCR, three out of the five most prevalent fears were associated with close relatives. DISCUSSION: FOP/FCR occurred frequently in more than one in three patients, but was mostly untreated in this sample of consecutive outpatients with CRC receiving oral capecitabine. In detail, most fears were related to family and friends. In addition to an unmet need of patients, our data indicate sources of distress not considered thus far. If replicated in larger studies, results may help to inform intervention development and improve patient care.
format Online
Article
Text
id pubmed-5694194
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56941942017-11-27 New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center Hefner, Jochen Berberich, Sara Lanvers, Elena Sanning, Maria Steimer, Ann-Kathrin Kunzmann, Volker Patient Prefer Adherence Original Research BACKGROUND: Fear of cancer progression/recurrence (FOP/FCR) is considered one of the most prevalent sources of distress in cancer survivors and associated with lower quality of life and functional impairment. Detailed measures of FOP/FCR are needed because little is known about the knowledge of FOP/FCR, its associations with the patient–doctor relationship, and the rate of adequate therapy. Colorectal cancer (CRC) is one of the most prevalent cancer entities, and oral capecitabine is widely prescribed as treatment. Therefore, we initiated a pilot study to expand the literature on FOP/FCR in CRC outpatients receiving capecitabine and to generate hypotheses for future investigations. METHODS: This study included 58 patients treated at a comprehensive cancer center. FOP/FCR was assessed with the Fear of Progression Questionnaire (FOP-Q-SF). Satisfaction with the relationships with doctors was assessed with the Patient–Doctor Relationship Questionnaire-9 (PRDQ-9). Levels of side effects were rated by the patients on a visual analog scale. Clinical data were extracted from the charts. RESULTS: A total of 19 out of 58 patients (36%) suffered from FOP/FCR according to our assessment. Levels of FOP/FCR seemed to be mostly moderate to high. Only four out of the 19 distressed patients (21%) were treated accordingly. Typical side effects of oncological treatment were associated with higher FOP/FCR. Satisfaction with doctor–patient relationships was not associated with FOP/FCR. Regarding single items of FOP/FCR, three out of the five most prevalent fears were associated with close relatives. DISCUSSION: FOP/FCR occurred frequently in more than one in three patients, but was mostly untreated in this sample of consecutive outpatients with CRC receiving oral capecitabine. In detail, most fears were related to family and friends. In addition to an unmet need of patients, our data indicate sources of distress not considered thus far. If replicated in larger studies, results may help to inform intervention development and improve patient care. Dove Medical Press 2017-11-14 /pmc/articles/PMC5694194/ /pubmed/29180853 http://dx.doi.org/10.2147/PPA.S142784 Text en © 2017 Hefner et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title_full New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title_fullStr New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title_full_unstemmed New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title_short New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center
title_sort new insights into frequency and contents of fear of cancer progression/recurrence (fop/fcr) in outpatients with colorectal carcinoma (crc) receiving oral capecitabine: a pilot study at a comprehensive cancer center
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694194/
https://www.ncbi.nlm.nih.gov/pubmed/29180853
http://dx.doi.org/10.2147/PPA.S142784
work_keys_str_mv AT hefnerjochen newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter
AT berberichsara newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter
AT lanverselena newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter
AT sanningmaria newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter
AT steimerannkathrin newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter
AT kunzmannvolker newinsightsintofrequencyandcontentsoffearofcancerprogressionrecurrencefopfcrinoutpatientswithcolorectalcarcinomacrcreceivingoralcapecitabineapilotstudyatacomprehensivecancercenter